Projected benefits of gout control on the health and economic burden of CKD patients with uncontrolled gout
This poster, presented at the annual meeting of the American Society of Nephrology in Philadelphia, USA (November, 2023) outlines the findings of a study examining the potential benefits of serum urate (SU) lowering using pegloticase in chronic kidney disease (CKD) patients with refractory gout. The study, using microsimulation modelling, found that under a pegloticase intervention scenario, 353,000 more gout cases were controlled, and 264,000 fewer patients had tophi, by 2035, compared to the baseline scenario. Further, the SU lowering intervention was projected to save $27.8B, and gain 7.7M working days, cumulatively through 2035. This study consequently provides evidence that successful treat-to-target urate-lowering could result in health, economic, and quality of life improvements for gout patients.
The Present and Future Health and Economic Burden of Controlled and Uncontrolled Gout in Patients with CKD in the US
This poster, presented at EULAR 2023, showcases our new research that projects the increasing health and economic burden of comorbid gout and CKD, in the US, between 2023 and 2035. This study is the first to project the burden of comorbid gout and CKD and highlights the need for strategies that can effectively control gout in CKD patients.